Autoimmune & immunology · Phase II

Top sponsors

• Takeda 26 programs
• Teva Pharma 13 programs
• Lakefront Biotherapeutics NV 12 programs
• Anaxis Pharma 11 programs
• Chinese Academy of 11 programs
• Novartis India 11 programs
• Sanofi-Aventis U.S 10 programs
• Pacira Ireland 9 programs
• United Therapeutics Europe 8 programs
• RIGEL PHARMACEUTICALS 6 programs
• Regeneron UK 6 programs
• Vertex Pharmaceuticals (Australia) 6 programs

1. -aminosalicylic acid

   Ultragenyx UK Limited

   Ulcerative Colitis

   phase 2 · small molecule · completed

   1 trial →

2. 114055

   GlaxoSmithKline

   Systemic Lupus Erythematosus

   phase 2 · small molecule · active

   1 trial →

3. 1425-0003

   Boehringer Ingelheim

   Crohn`s Disease (CD)

   phase 2 · small molecule · active

   1 trial →

4. 1509-0004

   Boehringer Ingelheim

   Systemic lupus erythematosus

   phase 2 · small molecule · active

   1 trial →

5. 200908

   GlaxoSmithKline

   Systemic Lupus Erythematosus

   phase 2 · small molecule · active

   1 trial →

6. 20170104

   Amgen

   Ulcerative Colitis (UC)

   phase 2 · other · active

   1 trial →

7. 20210210

   Amgen

   Ulcerative Colitis (UC)

   phase 2 · other · active

   1 trial →

8. 2022/3418 INDIGO

   The George Institute

   Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

   phase 2 · other · active

   1 trial →

9. 3133003

   Orion Laboratories Pty.

   Chronic Pain due to Ostheoarthritis of the knee

   phase 2 · small molecule · active

   1 trial →

10. 608

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Axial Spondyloarthritis

    phase 2 · small molecule · active

    1 trial →

11. 626

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Systemic Lupus Erythematosus (SLE)

    phase 2 · small molecule · active

    1 trial →

12. 627

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Ulcerative Colitis (UC)

    phase 2 · small molecule · active

    1 trial →

13. 68Ga-FAPI-46, Sonelokimab

    MoonLake Immunotherapeutics

    psoriatic arthritis, axial spondyloarthritis

    phase 2 · small molecule · active

    1 trial →

14. 75mg SHP647 (PF-00547659)

    Takeda

    Ulcerative Colitis

    phase 2 · small molecule · completed

    1 trial →

15. 77242113UCO2001

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 2 · small molecule · active

    1 trial →

16. 78934804CRD2001

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 2 · small molecule · active

    1 trial →

17. 78934804UCO2001

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 2 · small molecule · active

    1 trial →

18. 80 mg DR-6MP

    Teva Pharma GmbH

    Crohn's Disease

    phase 2 · small molecule · terminated

    1 trial →

19. 88545223PSA2001

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 2 · small molecule · active

    1 trial →

20. A-623

    Santhera Pharmaceuticals (Deutschland) GmbH

    Systemic Lupus Erythematosus

    phase 2 · small molecule · completed

    1 trial →

21. AB-101-05

    Artiva Biotherapeutics

    Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Sjögren’s Disease (SjD)

    phase 2 · small molecule · active

    1 trial →

22. ABBV-066, Lutikizumab

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 2 · small molecule · active

    1 trial →

23. ABBV-154

    AbbVie

    Crohn's Disease

    phase 2 · small molecule · terminated

    1 trial →

24. ACP-044 Dose A

    Acadia Pharmaceuticals B.V.

    Osteoarthritis Pain

    phase 2 · small molecule · terminated

    1 trial →

25. ADX-629

    Aldeyra Therapeutics

    Plaque Psoriasis

    phase 2 · small molecule · completed

    1 trial →

26. AGMB-129

    Agomab Therapeutics NV

    Fibrostenotic Crohn's Disease

    phase 2 · small molecule · active

    2 trials →

27. ALPN-101

    Vertex Pharmaceuticals (Australia) Pty.

    Systemic Lupus Erythematosus

    phase 2 · small molecule · completed

    1 trial →

28. ALX-0061

    Sanofi Pasteur

    Lupus Erythematosus, Systemic

    phase 2 · mab · completed

    1 trial →

29. ALX-0600

    Takeda

    Crohn's Disease

    phase 2 · small molecule · completed

    1 trial →

30. ALXN 2050, ALXN2050 Placebo Tablets

    Alexion Europe SAS

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 · small molecule · active

    1 trial →

31. ALXN1210-NEPH-202

    Alexion Europe SAS

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 · small molecule · active

    1 trial →

32. APHP180572

    Pari Pharma GmbH

    Ulcerative Colitis

    phase 2 · small molecule · active

    1 trial →

33. APHP220934

    Pari Pharma GmbH

    AXIAL SPONDYLOARTHRITIS

    phase 2 · small molecule · active

    1 trial →

34. APL-2

    Apellis Europe B.V.

    Warm Autoimmune Hemolytic Anemia

    phase 2 · small molecule · completed

    1 trial →

35. ARGX-117, ARGX-113

    argenx

    AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

    phase 2 · small molecule · active

    1 trial →

36. ARQ-151 cream 0.3%

    Arcutis Biotherapeutics

    Psoriasis

    phase 2 · small molecule · completed

    2 trials →

37. ARQ-151 cream 0.5%

    Arcutis Biotherapeutics

    Psoriasis

    phase 2 · small molecule · completed

    1 trial →

38. ASP5094

    Astellas Pharma Inc

    Rheumatoid Arthritis (RA)

    phase 2 · small molecule · completed

    1 trial →

39. ATI-450

    Aclaris Therapeutics

    Psoriatic Arthritis

    phase 2 · small molecule · terminated

    1 trial →

40. ATI-450

    Aclaris Therapeutics

    Rheumatoid Arthritis

    phase 2 · small molecule · completed

    1 trial →

41. ATI-450 50 mg oral tablet BID

    Aclaris Therapeutics

    Rheumatoid Arthritis

    phase 2 · small molecule · completed

    1 trial →

42. AUR-200-2024-02

    Aurinia Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 2 · small molecule · active

    1 trial →

43. AUTO1-SL2

    Autolus GmbH

    Systemic Lupus Erythematosus with Active Lupus Nephritis

    phase 2 · small molecule · active

    1 trial →

44. AZD1163 Placebo, AZD1163

    AstraZeneca AB

    Rheumatoid arthritis

    phase 2 · small molecule · active

    1 trial →

45. AZD7798 Placebo, AZD7798

    AstraZeneca AB

    Crohn's Disease

    phase 2 · small molecule · active

    1 trial →

46. Alicaforsen

    IONIS PHARMACEUTICALS INC

    Ulcerative Colitis

    phase 2 · small molecule · completed

    2 trials →

47. Allogeneic MSC (AlloMSC)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory Systemic Lupus Erythematosus

    phase 2 · mab · active

    1 trial →

48. Allogeneic NK Cells

    Artiva Biotherapeutics

    Refractory Rheumatoid Arthritis (RA)

    phase 2 · small molecule · active

    1 trial →

Frequently asked questions